Summary: H.R.3379 — 116th Congress (2019-2020)All Information (Except Text)

There is one summary for H.R.3379. Bill summaries are authored by CRS.

Shown Here:
Introduced in House (06/20/2019)

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.

This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.